dhr. prof. dr. G.D. Laverman

Aandachtsgebieden

BIG-nummer

Wetenschappelijke publicaties en onderzoeken

• Blood Pressure Control in the DIAbetes and LifEstyle Cohort Twente (DIALECT): The Role of Patient Adherence and Physician’s Follow-Up Action.

  Dam SL(ZGT), Masselink-Haverkate HM(ZGT), Gant GM, Bakker SJL, NIjboer RM(ZGT), Kruik-Kollöffel WJ, Laverman GD.
  Pharmacoepidemiology 2023; 2:307–319.
  

• Effects of albuminuria-lowering treatments on inflammation markers: A post hoc analysis from the ROTATE trials

  Sen T, Rotbain Curovic V, Jongs N, Laverman GD, Kooy A, Persson F, Rossing P, Heerspink HJL.
  Diabetes Obes Metab. 2023; 25(8):2413-2418.
  

• Cognitive Bias Modification Training Targeting Fatigue in Patients With Kidney Disease: Usability Study

  Geerts J, Pieterse M, Laverman GD, Waanders F, Oosterom N(ZGT), Slegten J, Salemink E, Bode C.
  JMIR Form Res. 2023; :Doi: 10.2196/43636..
  

• Presence of retinopathy and incident kidney and cardiovascular events in type 2 diabetes with normoalbuminuria - A post-hoc analysis of the PRIORITY randomized clinical trial

  Rotbain Curovic V, Tofte N, Lindhardt M, Adamova K, Bakker SJL, Beige J, Beulens JWJ, Birkenfeld AL, Currie G, Delles C, Laverman GD.
  J Diabetes Complications 2023; 37(4):108433.
  

• Cadmium, active smoking and renal function deterioration in patients with type 2 diabetes

  Oosterwijk MM(ZGT), Hagedoorn IJM(ZGT), Maatman RGH, Bakker SJL, Navis G, Laverman GD.
  Nephrol Dial Transplant. 2023; 38(4):876-883.
  

• Adherence to Statin Therapy and Attainment of LDL Cholesterol Targets in an Outpatient Population of Type 2 Diabetes Patients: Analysis in the DIAbetes and LifEstyle Cohort Twente (DIALECT)

  Beernink J(ZGT), Oosterwijk MM(ZGT), Boven JFM van , Heersprink HJL, Bakker SJL, Navis G, Nijboer RM(ZGT), Gant CM, Haverkate H(ZGT), Kruik-Kollöffel WJ, Laverman GD.
  Frontiers in Pharmcology 2022; :doi: 10.3389/fphar.2022.888110 EPUB..
  

• Effects of dapagliflozin on volume status and systemic hemodynamics in patients with CKD without diabetes: Results from DAPASALT and DIAMOND

  Sen T, Scholtes R, Greasley PJ, Cherney D, Dekkers CCJ, Vervloet M, Danser AHJ, Barbour S, Karlsson C, Laverman GD.
  Diabetes Obes Metab. 2022; :doi: 10.1111/dom.14729. Online ahead of print..
  

• Urinary creatinine excretion is an indicator of physical performance and function

  Oosterwijk MM(ZGT), Braber N den , Bakker SJL, Laverman GD.
  J Cachexia Sarcopenia Muscle. 2022; 13(2):1431-1433.
  

• Renal haemodynamic response to sodium-glucose cotransporter-2 inhibition does not depend on protein intake: An analysis of three randomized controlled trials

  Aart-van der Beek AB van der, Cherney D, Laverman GD, Stefansson B, Raalte DH van , Hoogenberg K, Reyner D, Li Q, Tanna GL Di, Greasley PJ, Heerspink HJL.
  Diabetes Obes Metab . 2021; :doi: 10.1111/dom.14411. Online ahead of print..
  

• Evaluation of the Pharmacokinetics and Exposure-Response Relationship of Dapagliflozin in Patients without Diabetes and with Chronic Kidney Disease

  Aart-van der Beek AB van der, Koomen JV, Dekkers CCJ, Barbour SJ, Boulton DW, Gansevoort RT, Abdul Gafo AH, Laverman GD, Li Q, Stevens J.
  Clin Pharmacokinet 2021; 60(4):517-525.
  

• Biochemical Urine Testing of Medication Adherence and Its Association With Clinical Markers in an Outpatient Population of Type 2 Diabetes Patients: Analysis in the DIAbetes and LifEstyle Cohort Twente (DIALECT)

  Beernink JM, Oosterwiijk MM(ZGT), Khunti K, Gupta P, Patel P, Boven JFM van , Heerspink HJL, Bakker SJL, Navis G, Nijboer RM(ZGT), Laverman GD.
  Diabetes Care 2021; :doi: 10.2337/dc20-2533. Online ahead of print..
  

• Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial

  Cherney DZI, Dekkers CCJ, Barbour SJ, Cattran D, Abdul Gafor AH, Greasley PJ, Laverman GD, Lim SK, .
  Lancet Diabetes Endocrinol. 2020; 8(7):582-593.
  

• A Self-management Approach for Dietary Sodium Restriction in Patients With CKD: A Randomized Controlled Trial

  Humalda JK, , Klaassen G, Vries H de , Meuleman Y, Verschuur LC, Straathof EJM, Laverman GD, Bos WJW, Boog PJM van der , SUBLIME Investigators .
  Am J Kidney Dis. 2020; 75(6):847-856.
  

• Early Detection of Diabetic Kidney Disease by Urinary Proteomics and Subsequent Intervention With Spironolactone to Delay Progression (PRIORITY): A Prospective Observational Study and Embedded Randomised Placebo-Controlled Trial

  Tofte N, Lindhardt M, Adamova K, Bakker SJL, Beige J, Beulens JWJ, Birkenfeld AL, Currie G, Delles C, Dimos I, Laverman GD.
  Lancet Diabetes Endocrinol. 2020; 4:301-312.
  

• Fibroblast Growth Factor 23 and Mortality in Patients With Type 2 Diabetes and Normal or Mildly Impaired Kidney Function

  Yeung SMH, Binnenmars SH, Gant CM, Navis G, Gansevoort RT, BAkker SJL, Borst MH de , Laverman GD.
  Diabetes Care 2019; 42(11):2151-2153.
  

• Impact of Moderate Sodium Restriction and Hydrochlorothiazide on Iodine Excretion in Diabetic Kidney Disease: Data from a Randomized Cross-Over Trial.

  Binnenmars SH, Corpeleijn E, Kwakernaak AJ, Touw DJ, Kema IP, Laverman GD, Bakker SJL, Navis G.
  Nutrients. 2019 Sep 12;11(9). pii: E2204. 2019; :doi: 10.3390/nu11092204 [epub ahead of print].
  Publicatie openen

• Effects of Dapagliflozin on Volume Status When Added to Renin-Angiotensin System Inhibitors

  Eickhoff MK, Dekkers CC, Kramers BJ, Laverman GD, Frimodt-Møller M, Jørgensen NR, Faber J.
  J.Clin. Med. 2019; 8(6). :pii: E779.
  Publicatie openen

• Escaping residual albuminuria in hypertension: should we start eplerenone or reduce salt intake?

  Borst MH de , Laverman GD, Navis G.
  Hypertens Res. 2019; 42(4)::583-585.
  Publicatie openen

• High Dietary Intake of Vegetable Protein Is Associated With Lower Prevalence of Renal Function Impairment

  Oosterwijk MM, Soedamah-Muthu SS, Geleijnse JM, Bakker SJ, Navis G, Binnenmars SH, Gant CM, Laverman GD.
  Kidney Int Rep. 2019; 4(5):710-719.
  Publicatie openen

• Requirements of an Application to Monitor Diet, Physical Activity and Glucose Values in Patients with Type 2 Diabetes: The Diameter.

  Braber N den, Vollenbroek-Hutten MM, Oosterwijk MM, Gant CM, Hagedoorn IJ, Beijnum BF van, Hermens HJ, Laverman GD.
  Nutrients 2019; 11(2). :pii: E409.
  Publicatie openen

• Emergence of tick-borne encephalitis (TBE) in the Netherlands

  Dekker-Jansen MMG, Laverman GD, Vries A de , Reimerink J, Geeraedts FCG.
  Ticks Tick Borne Dis. 2019; 10(1)::176-179.
  Publicatie openen

• Emergence of tick-borne encephalitis (TBE) in the Netherlands.

  Dekker M, Laverman GD, Vries A de , Reimerink J, Geeraedts F.
  Ticks Tick Borne Dis. 2018; 10(1):176-9..
  Publicatie openen

• Detection of carnosinase-1 in urine of healthy individuals and patients with type 2 diabetes correlation with albuminuria and renal function.

  Rodriguez-Niño A, Gant CM, Braun JD, Li X, Zhang S, Albrecht T, Qiu J, Bakker SJ, Laverman GD.
  Amino Acids 2018; : doi: 10.1007/s00726-018-2602-y. [Epub ahead of print].
  Publicatie openen

• Correlations between plasma strontium concentration, components of calcium and phosphate metabolism and renal function in type 2 diabetes mellitus.

  Berkhof YS van den, Gant CM, Maatman RGHJ, Graaf A de , Navis GJ, Bakker SJ, Laverman GD.
  Eur J Clin Invest. 2018; :doi: 10.1111/eci.12987. [Epub ahead of print].
  Publicatie openen

• Glycaemic control in the diabetes and Lifestyle Cohort Twente: A cross-sectional assessment of lifestyle and pharmacological management on Hba1c target achievement.

  Jalving AC, Gant CM, Binnenmars SH, Soedamah-Muthu SS, Bakker SJ, Navis G, Laverman GD.
  Diabetes Obes Metab. 2018; :doi: 10.1111/dom.13399. [Epub ahead of print].
  Publicatie openen

• Lower Renal Function Is Associated With Derangement of 11-β Hydroxysteroid Dehydrogenase in Type 2 Diabetes

  Gant CM, Minovic I, Binnenmars H, Vries L de , Kema I, Beek A van , Navis G, Bakker S, Laverman GD.
  J Endocr Soc. 2018; 2(7):609-620.
  Publicatie openen

• Real-life achievement of lipid-lowering treatment targets in the DIAbetes and LifEstyle Cohort Twente: systemic assessment of pharmacological and nutritional factors

  Gant CM, Binnenmars SH, Harmelink M, Soedamah-Muthu SS, Bakker SJ, Navis G, Laverman GD.
  Nutr Diabetes. 2018; 8(1):24-.
  Publicatie openen

• Physical Activity in Patients With Type 2 Diabetes: The Case for Objective Measurement in Routine Clinical Care

  Oosterom N, Gant CM, Ruiterkamp N, Beijnum BF van , Hermens H, Bakker SJ, Navis G, Vollenbroek-Hutten MM, Laverman GD.
  Diabetes Care. 2018; Apr;41(4)::e50-e51.
  Publicatie openen

• Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers

  Dekkers CC, Petrykiv S, Laverman GD, Cherney DZ, Gansevoort RT, Heerspink HJ.
  Diabetes Obes Metab. 2018; :doi: 10.1111/dom.13301. [Epub ahead of print].
  

• Higher Dietary Magnesium Intake and Higher Magnesium Status Are Associated with Lower Prevalence of Coronary Heart Disease in Patients with Type 2 Diabetes

  Gant CM, Soedamah-Muthu SS, Binnenmars SH, Bakker SJ, Navis G, Laverman GD.
  Nutrients 2018; :doi: 10.3390/nu10030307[epub ahead of print].
  Publicatie openen

• Renoprotective RAAS inhibition does not affect the association between worse renal function and higher plasma aldosterone levels

  Gant CM, Laverman GD, Vogt L, , Heerspink HJ, Waanders F, Hemmelder MH, Navis G.
  BMC Nephrol. 2018; :doi: 10.1186/s12882-017-0789-x.
  Publicatie openen

• Pooled Analysis of Multiple Crossover Trials To Optimize Individual Therapy Response to Renin-Angiotensin-Aldosterone System Intervention

  Petrykiv SI, Laverman GD, Persson F, Vogt L, Rossing P, Borst MH de , Gansevoort RT, .
  Clin J Am Soc Nephrol. 2017; 12(11):1804-1813.
  Publicatie openen

• Does SGLT2-inhibition with dapagliflozin overcome individual therapy resistance to RAAS inhibition?

  Petrykiv S, Laverman GD, Zeeuw D de , Heerspink HJ.
  Diabetes Obes Metab. 2017; :doi: 10.1111/dom.13057.
  Publicatie openen

• Integrated Assessment of Pharmacological and Nutritional Cardiovascular Risk Management: Blood Pressure Control in the DIAbetes and LifEstyle Cohort Twente

  Gant CM, Binnenmars SH, Berg EV, Bakker SJ, Navis G, Laverman GD.
  Nutrients 2017; 9(7):pii: E709.
  Publicatie openen

• Variability in response to albuminuria lowering drugs: true or random?

  Petrykic SI, Zeeuw D de, Persson F, Rossing P, Gansevoort RT, Laverman GD, Heerspink HJ.
  Br J Clin Pharmacol 2017; 83(6):1197-1204.
  Publicatie openen

• Gender Differences in Renin Angiotensin Aldosterone System Affect Extra Cellular Volume in Healthy Subjects

  Toering TJ, Gant CM, Visser FW, Graaf AM van der , Laverman GD, Danser AH, Faas MM, Navis G, Ley AT.
  Am J Physiol Renal Physiol 2017; :10.1152/ajprenal.00109.2017.
  Publicatie openen

• Increasing evidence of tick-borne encephalitis (TBE) virus transmission, the Netherlands, June 2016

  Weststrate AC, Knapen D, Laverman GD, Schot BW, Prick JJW, Spit SA.
  Euro Surveill. 2017; 22(11):10.2807/1560-7917.ES.2017.22.11.30482.
  Publicatie openen

• The albuminuria-lowering response to dapagliflozin is variable and reproducible among individual patients

  Petrykiv SI, Laverman GD, Zeeuw D de , Heerspink HJL.
  Diabetes Obes Metab 2017; :10.1111/dom.12936.
  Publicatie openen

• Effects of Direct Renin Blockade on Renal & Systemic Hemodynamics and on RAAS Activity, in Weight Excess and Hypertension: A Randomized Clinical Trial

  Kwakernaak AJ, Roksnoer LC, Lambers Heerspink HJ, Berg-Garrelds I van den, Lochorn GA, Laverman GD.
  PLos One 2017; 12(1):10.1371/journal.pone.0169258.
  Publicatie openen

• Effects of Vitamin D Receptor Activation and Dietary Sodium Restriction on Residual Albuminuria in CKD: The ViRTUE-CKD Trial

  Keyzer CA, Breda GF van, Vervloet MG, Jong MA de, Laverman GD, Hemmelder MH, Janssen WM, Lambers Heerspink HJ, Kwakernaak AJ, Bakker SJ, Navis G, Borst MH de, Laverman GD.
  J Am Soc Nephrol 2016; :pii: ASN.2016040407 [Epub ahead of print].
  Publicatie openen

• Vitamin D receptor activator and dietary sodium restriction to reduce residual urinary albumin excretion in chronic kidney disease (ViRTUE study): rationale and study protocol

  Keyzer CA, Jong MA de, Fenna van Breda G, Vervloet MG, Laverman GD, Hemmelder M, Janssen WM, Lambers Heerspink HJ, Navis G, Borst MH de .
  Nephrol Dial Transplant   2016; 31 (7) :1081-7.
  Publicatie openen

• The 'sublime' approach: cost-efficacy of a novel self-management approach for dietary sodium restriction in CKD patients

  Humalda JK, Klaassen G, Vries PAM de, Meuleman Y, Laverman GD, Bos WJ, Boog PJM van der, Vermeulen KM, Henkemans OA, Otten W.
  NEPHROL DIAL TRANSPLANT 2016; 31(S1):206-207.
  

• Concordance of Dietary Sodium Intake and Concomitant Phosphate Load: Implications for Sodium Interventions

  Humalda JK, Keyzer CA, Binnenmars SH, Kwakernaak AJ, Slagman MC, Laverman GD, Bakker SJ, Borst MH de, Navis GJ.
  Nutrition, metabolism & cardiovasc dis. 2016; 8 april:.
  Publicatie openen

• Distal Renal Tubular Acidosis With Multiorgan Autoimmunity: A Case Report

  Wildenberg MJ van den , Hoorn EJ, Mohebbi N, Wagner CA, , Vries PAM de, Laverman GD.
  Am J Kidney Dis. 2015; 65(4):607-10.
  Publicatie openen

• Distal Renal Tubular Acidosis With Multiorgan Autoimmunity: A Case Report

  Wildenberg MJ van den, Hoorn EJ, Mohebbi N, Wagner CA, Woittiez AJ, Vries PAM de, Laverman GD.
  Am J Kidney Dis 2014; :Epub Dec 18.
  Publicatie openen

• Microbial aortitis with aneurysm formation

  Raghoo R, Noeverman MJ, Hoekstra R, Geekerken R, Laverman GD.
  World J Cardiovasc Surg 2014; 4:181-185.
  Publicatie openen

• Prolonged hypocalcaemia after pamidronate infusion in Riedel's thyroiditis associated hypoparathyroidism

  Boumans D, Vries PAM de, Rikken NET, Laverman GD.
  Neth J Med 2014; 71(8):442-3.
  

• Bilateral dacryoadenitis as a presenting symptom of an extra-ocular disease

  Wildenberg MJ van den, Laverman GD, Vries PAM de.
  Neth J Med 2014; 72(5):281-285.
  Publicatie openen

• The Biobank of Nephrological Diseases in the Netherlands cohort: the String of Pearls Initiative collaboration on chronic kidney disease in the university medical centers in the Netherlands

  Navis GJ, Blankestijn PJ, Deegens J, Fijter JW de, Homan van der Heide JJ, Rabelink T, Krediet RT, Kwakernaak AJ, Laverman GD, Leunissen KM, Paassen P van, Vervloet MG, Wee PM, Wetzels JF, Zietse R, Ittersum FJ van.
  Nephrol Dial Transplant 2014; 29(6):1145-50.
  Publicatie openen

• Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial

  Kwakernaak AJ, Krikken JA, Binnenmars SH, Visser FW, Hemmelder MH, Woittiez AJ, Groen H, Laverman GD, Navis G.
  Lancet Diabetes Endocrinol 2014; 2(5):385-95. doi: 10.1016/S2213-8587(14)70030-0 Epub 2014 Mar 5..
  Publicatie openen

• A False-positive Antineutrophil Cytoplasmic Antibody Proteinase 3 Test in a Patient with Pulmonary-renal Syndrome

  Agterhuis DE, Mulder AHL, Roozendaal C, Stegeman CA, Laverman GD.
  J Rheumatol 2014; 41(5):1031-3. doi:10.3899/jrheum.131205.
  Publicatie openen

• False-positive Antineutrophil Cytoplasmic Antibody Proteinase 3 Test in a Patient with Pulmonary-renal Syndrome

  Agterhuis DE, Mulder AHL, Roozendaal C, Stegeman CA, Laverman GD.
  J Rheumatol 2014; 41(5):1031-3.
  

• Quiz page february 2014: swollen kidneys and a pancreatic mass

  Agterhuis DE, Schuurmans EP, Hogenes MC, Laverman GD.
  Am J Kidney Dis 2014; 63(2):A18-21.
  

• The Biobank of Nephrological Diseases in the Netherlands cohort

  Navis GJ, Blankestijn PJ, Deegens J, Fijter JW de, Homan van der Heide JJ, Rabelink T, Krediet RT, Kwakernaak AJ, Laverman GD, Leunissen KM, Paassen P van, Vervloet MG, Wee PM, Wetzels JF, Zietse R, Ittersum FJ van, .
  Nephrol Dial Transplant. 2013; 22:.
  Publicatie openen

• Sodium restriction on top of rennin-angiotensin-aldosterone system blockade

  Kwakernaak AC, Waanders F, Slagman MC, Dokter MM, Laverman GD, Boer RA de, Navis G.
  J Hypertens. 2013; 11:.
  Publicatie openen

• Proprotein convertase subtilisin-kexin type 9 is elevated in proteinuric subjects: relationship with lipoprotein response to antiproteinuric treatment

  Kwakernaak AJ, Lambert G, Slagman MC, Waanders F, Laverman GD, Petrides F, Dikkeschei BD, Navis G, Dullaart RP.
  Atherosclerosis 2013; 226(2):459-65.
  Publicatie openen

• Proprotein convertase subtilisin-kexin type 9 is elevated in proteinuric subjects: relationship with lipoprotein response to antiproteinuric treatment

  Kwakernaak AJ, Lambert G, Slagman MC, Waanders GD, Laverman GD.
  Atherosclerosis 2012; 29:[Epub ahead of print].
  Publicatie openen

• A spangled colon

  Raghoo R, Laverman GD, , , Vries PAM de.
  Neth J Med 2012; 70:376-380.
  Publicatie openen

• Performance of MDRD study and CKD-EPI equations for long term follow-up of non-diabetic patients with chronic kidney disease

  Tent H, Waanders F, Krikken JA, Lambers Heerspink HJ, Stevens LA, Laverman GD.
  Nephrol Dial Transplant 2012; 27(s3):i89-i95.
  Publicatie openen

• Vitamin K intake and plasma desphospho-uncarboxylated matrix levels in kidney transplant recipients

  Laverman GD, Schurgers LJ, Kema IP, Muskiet FA.
  PLos One 2012; 7:e47991.
  Publicatie openen

• Epstein-Barr virus-posïtive post-transplant lymphoproliferative disorder of the central nervous system after renal transplantation with a discrepancy in viral load between peripheral blood and cerebrospinal fluid

  Boersma MN, Zanden A van der, Laverman GD, Sanders JS, Vries PAM de.
  Transplant Internat 2012; 25 (D1):13-e11.
  Publicatie openen

• Indomethacin reduces glomerular and tubular damage markers but not renal inflammation in chronic kidney disease patients: a post-hoc analysis.

  Borst MH de, Nauta FL, Vogt L, Laverman GD, Gansevoort RT, Navis G.
  PLoS One 2012; 7:e37957.
  Publicatie openen

• Vitamin K intake and status are low in hemodialysis patients

  Cranenburg EC, Schurgers LJ, Uiterwijk HH, Beulens JW, Dalmeijer GW, Laverman GD.
  Kidney Internat 2012; 82:605-610.
  Publicatie openen

• Elevated N-terminal pro-brain natriuretic peptide (NT-proBNP) levels indicate volume –dependent hypertension and proteinuria in renal disease: implications for therapeutic intervention.

  Slagman MC, Waanders F, Vogt L, Damman K, Hemmelder MH, Laverman GD.
  Nephrol Dial Transplant 2012; 27:983-990.
  Publicatie openen

• Vascular endothelial growth factor C levels are modulated by dietary salt intake in proteinuric chronic kidney disease patients and in healthy subjects

  Slagman MC, Kwakernaak AJ, Yazdani S, Laverman GD, Born J van den .
  Nephrol Dial Transplant 2012; 27:978-982.
  Publicatie openen

• An initial reduction in serumuric acid during angiotensin receptor blocker treatment is associated with cardiovascular protection: a post-hoc analysis of the RENAAL and IDNT trials

  Smink PA, Bakker SJ, Laverman GD, Berl T, Cooper ME.
  J Hypertens 2012; 30:1022-1028.
  Publicatie openen